Drug Updates

Subcategories:Analgesics Biologics/DMARDs

Biosimilar Drugs Face Challenges to Reach the U.S. Market

Kathleen Louden | March 8, 2012

To date, the FDA has not approved a biosimilar product. In its own discussion of the merits and obstacles to biosimilar drugs, the ACR sponsored a panel session titled, “Biosimilar Products in the U.S. Market: Fact or Fiction?” at the 2011 ACR/ARHP Annual Scientific Meeting here in November.

Where Will Kinase Inhibitors Fit into the RA Treatment Mix?

Vanessa Caceres | March 8, 2012

Presenters at “Looking Ahead to Kinase Inhibition in Rheumatoid Arthritis,” a session here at the 2011 ACR/ARHP Annual Scientific Meeting, delved into some of the big questions that rheumatology faces with kinase inhibitor use.

Information on New Drug Approvals and Medication Safety

Michele B. Kaufman, PharmD, BCGP | March 8, 2012

Rheumatology-related drug safety, approvals, and what’s in the pipeline.

Letter: RA Approval for IL-1Ra

William Arend, MD | February 3, 2012

Investors convinced the executives of Synergen that they needed to evaluate IL-1Ra for a disease with a more rapid outcome. RA studies were too slow to yield a quick profit. Thus, they picked sepsis syndrome.